| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,857 |
| 52
Week Range: |
$37.29 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
230,132 |
422,694 |
1,171,108 |
1,389,174 |
| Total Sell Value |
$15,188,297 |
$25,482,465 |
$68,628,084 |
$77,001,153 |
| Total People Sold |
8 |
9 |
11 |
11 |
| Total Sell Transactions |
20 |
41 |
78 |
81 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carey Stephen P. |
SVP AND CFO |
• – – |
2023-03-28 |
4 |
D |
$38.62 |
$54,840 |
D/D |
(1,420) |
137,486 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2023-03-23 |
4 |
D |
$37.82 |
$92,735 |
D/D |
(2,452) |
112,730 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2023-03-23 |
4 |
D |
$37.82 |
$660,148 |
D/D |
(17,455) |
250,840 |
|
- |
|
| Carey Stephen P. |
SVP AND CFO |
• – – |
2023-03-23 |
4 |
D |
$37.82 |
$159,752 |
D/D |
(4,224) |
138,906 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2023-03-07 |
4 |
D |
$44.23 |
$108,806 |
D/D |
(2,460) |
115,182 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2023-03-07 |
4 |
D |
$44.23 |
$84,125 |
D/D |
(1,902) |
37,660 |
|
- |
|
| Carey Stephen P. |
SVP AND CFO |
• – – |
2023-03-07 |
4 |
D |
$44.23 |
$154,938 |
D/D |
(3,503) |
143,130 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2023-03-07 |
4 |
D |
$44.23 |
$604,270 |
D/D |
(13,662) |
268,295 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2023-03-07 |
4 |
D |
$44.23 |
$103,587 |
D/D |
(2,342) |
34,027 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
40,526 |
178,012 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2023-02-15 |
4 |
D |
$45.04 |
$58,192 |
D/D |
(1,292) |
39,562 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2023-02-15 |
4 |
D |
$45.04 |
$57,426 |
D/D |
(1,275) |
36,369 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2022-12-01 |
4 |
S |
$38.50 |
$7,700,000 |
D/D |
(200,000) |
2,019,259 |
|
-0% |
|
| Davis Krista |
SVP, CHIEF HR OFFICER |
• – – |
2022-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
16,433 |
16,433 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2022-09-08 |
4 |
D |
$37.61 |
$137,126 |
D/D |
(3,646) |
281,957 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2022-08-15 |
4 |
S |
$37.79 |
$195,464 |
D/D |
(5,172) |
117,642 |
|
-3% |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2022-08-12 |
4 |
S |
$37.04 |
$477,605 |
D/D |
(12,894) |
122,814 |
|
-5% |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2022-07-18 |
4 |
A |
$0.00 |
$0 |
D/D |
19,280 |
19,280 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2022-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,644 |
135,708 |
|
- |
|
| Carey Stephen P. |
SENIOR VICE PRESIDENT AND CFO |
• – – |
2022-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
11,291 |
146,633 |
|
- |
|
| Pera Antonio R |
|
– • – |
2022-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
10,049 |
29,762 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2022-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,476 |
37,644 |
|
- |
|
| Walsh Patrick D |
|
– • – |
2022-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
10,049 |
63,437 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2022-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,476 |
40,854 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2022-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
33,352 |
285,603 |
|
- |
|
704 Records found
|
|
Page 6 of 29 |
|
|
0.59 (0.89%) 
